https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Phospho-heavy-labeled-spiketide FAIMS stepped-CV DDA (pHASED) provides real-time phosphoproteomics data to aid in cancer drug selection https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51137 Tue 22 Aug 2023 15:58:50 AEST ]]> Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44354 Tue 11 Oct 2022 19:42:45 AEDT ]]> The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50562 Tue 01 Aug 2023 10:19:27 AEST ]]> PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55040 Thu 04 Apr 2024 13:51:52 AEDT ]]> Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38260 9-tetrahydrocannabinol (∆⁹-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that ∆⁹-THC can inhibit the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1R and CB2R), but clinical confirmation remains lacking. In parallel, the anti-cancer properties of non-THC cannabinoids, such as cannabidiol (CBD), are linked to the modulation of non-CB1R/CB2R G-protein-coupled receptors, neurotransmitter receptors, and ligand-regulated transcription factors, which together modulate oncogenic signalling and redox homeostasis. Additional evidence has also demonstrated the anti-inflammatory properties of cannabinoids, and this may prove relevant in the context of peritumoural oedema and the tumour immune microenvironment. This review aims to document the emerging mechanisms of anti-cancer actions of non-THC cannabinoids.]]> Mon 29 Jan 2024 17:45:13 AEDT ]]> CAR T cell therapies for diffuse midline glioma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52367 Mon 13 Nov 2023 08:52:16 AEDT ]]> ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53140 Fri 17 Nov 2023 11:42:18 AEDT ]]> Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51529 Fri 08 Sep 2023 12:10:33 AEST ]]> B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51515 Fri 08 Sep 2023 12:04:15 AEST ]]>